Circulating miRNA Expression Is Inversely Correlated with Tumor Tissue or Sentinel Lymph Nodes in Estrogen Receptor-Positive Early Breast Cancer Patients.
Por:
Escuin D, López-Vilaró L, Bell O, Mora J, García-Valdecasas B, Moral A, Clos M, Boronat L, Arqueros C, Barnadas A
Publicada:
27 ago 2023
Ahead of Print:
27 ago 2023
Resumen:
The deregulation of microRNAs (miRNAs) is associated with the various steps of the metastatic process. In addition, circulating miRNAs are remarkably stable in peripheral blood, making them ideal noninvasive biomarkers for disease diagnosis. Here, we performed a proof-of-principle study to determine whether tumor-tissue-derived miRNAs are traceable to plasma in ER-positive early breast cancer patients. We performed RNA-sequencing on 30 patients for whom plasma, sentinel lymph nodes (SLNs) and tumor tissue were available. We carried out differential expression, gene ontology and enrichment analyses. Our results show that circulating miRNAs are inversely expressed compared with tumor tissue or SLNs obtained from the same patients. Our differential expression analysis shows the overall downregulation of circulating miRNAs. However, the expression of miR-643a-3p and miR-223 was up-regulated in patients with positive SLNs. Furthermore, gene ontology analysis showed the significant enrichment of biological processes associated with the regulation of epithelial cell proliferation and transcriptional regulation commonly involved in the promotion of metastases. Our results suggest the potential role of several circulating miRNAs as surrogate markers of lymph node metastases in early breast cancer patients. Further preclinical and clinical studies are required to understand the biological significance of the most significant miRNAs and to validate our results in a larger cohort of patients.
Filiaciones:
Escuin D:
Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain
López-Vilaró L:
Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain
Department of Pathology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Bell O:
Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain
Mora J:
Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
García-Valdecasas B:
Department of Surgery, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Moral A:
Department of Surgery, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Faculty of Medicine, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain
Clos M:
Department of Surgery, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Boronat L:
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Arqueros C:
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Barnadas A:
Institut d'Investigació Biomèdica Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain
Faculty of Medicine, Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain
Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
Centro de Investigación Biomédica en Red Cáncer (CIBERONC), 28029 Madrid, Spain
Green Published, gold, All Open Access, Gold, Green
|